Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

Calorie-managed diets and exercise have been the mainstay approach of commercial weight loss programs for decades. But as semaglutide weight loss medications like Ozempic, Wegovy and others become ...

Looking for successors to the blockbuster GLP-1 obesity drugs, companies like Novo Nordisk and Eli Lilly are testing amylin ...

Dudum said: “People believe that compounding cannibalises the market when the commercial drugs are available ... inspected ...

Broadening insurance coverage is another milestone for Wegovy, which, like its diabetes drug cousin Ozempic, has become a cultural sensation and blockbuster. The move by CMS could also add pressure on ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better ...

Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...

This summary presents key updates in the health sector. Highlights include UnitedHealth's tech unit customers adopting ...

Pemvidutide's potential in obesity and MASH, combined with lean mass preservation, could make it a market leader in the ...